Latest news
Stay up to date
Receive updates on new technology developments, market and industry trends, special events, Mayo Clinic technologies available for licensing, and more.
Fierce Biotech | November 8, 2022
PR Newswire | November 8, 2022
FiercePharma | October 25, 2022
Biz Journals | October 20, 2022
Post Bulletin | October 20, 2022
EXCERPT: “Today’s Investment in Healing Conference brought together key collaborators who are playing a pivotal role in the creation of a dynamic platform ecosystem,” wrote Mayo Clinic President and CEO Dr. Gianrico Farrugia.
Mayo Clinic News Network | October 12, 2022
Healthcare IT News | October 3, 2022
MobiHealthNews | September 21, 2022
BioSpace | September 20, 2022
EXCERPT:Â Â MoatBio holds an exclusive patent license from Mayo Clinic for the novel second generation single-cycle adenovirus vaccine platform (SC-AdVax) to develop intranasal and oral vaccines that can elicit and boost both mucosal and systemic immunity for the treatment of infectious diseases, like COVID-19.Â
Twin Cities Business | September 1, 2022
EXCERPT:Â Mayo Clinic Ventures chair Andrew Danielsen estimated that the accelerator will give birth to about one to three new companies a year.
Mayo Clinic, Hibiscus BioVentures and Innoforce announce Mayflower cell and gene therapy accelerator
Mayo Clinic News Network | August 31, 2022
PR Newswire | August 29, 2022
Fierce Pharma | August 18, 2022
Mayo Clinic News Network | August 15, 2022
Mass Device | August 1, 2022
EXCERPT:Â Mayo Clinic participated, making the Israel-based firm a Mayo Clinic portfolio company.
Business Wire | July 20, 2022
Mayo Clinic News Network | July 19, 2022
Med City News | July 15, 2022
EXCERPT: Anumana was formed by Mayo Clinic and nference, a company that uses unstructured electronic medical records data from medical centers to develop new diagnostics and treatments.
Fierce Biotech | July 14, 2022
Mayo Clinic News Network | June 21, 2022
Fierce Healthcare | June 20, 2022
Mass Devices | May 24, 2022
EXCERPT: The algorithm is Anumana’s second to receive a breakthrough nod, with its low ejection fraction algorithm (developed by Mayo Clinic and licensed by Anumana) garnering approval in 2019, plus FDA emergency use authorization (EUA) for COVID-19 in 2020.